Transthyretin Amyloidosis (ATTR) for Professionals
Participation in activities of daily life can be challenging for those with ATTR-CM, a restrictive cardiomyopathy produced by extracellular deposition of transthyretin.
Geographic and racial healthcare disparities add to the burden of disease. Shared decision making and early detection with readily available noninvasive tests, among other strategies, are essential as therapy for ATTR-CM.
Videos On Demand
Recognize the Complexities of Transthyretin Amyloidosis (ATTR)
The clinical presentation of ATTR may be hidden in plain sight. In these continuing education activities explore the varied clinical presentations of amyloidosis in different organ systems including the heart, nervous system, gastro-intestinal tract, and kidneys. Get the facts from an expert panel on how to recognize and treat the complexities of this progressive, degenerative, and multisystemic disorder.
Podcasts
Extra-Cardia Clues to Amyloidosis
This podcast will offer guidance on early identification of non-cardiac manifestations of amyloidosis from the perspective of the Gastrointestinal and Neurology clinical communities.
Future Directions and Areas of Uncertainty for ATTR:
Where will we be in the next decade?
This podcast explores key uncertainties and future directions in screening, diagnosis, risk assessment, and management of ATTR cardiac amyloidosis. It also examines how social determinants of health affect access to diagnosis and treatment, and highlights gaps in tools for monitoring disease progression.
Unraveling the Mysteries of ATTR
Exploring Diagnostic Challenges, Laboratory Tests, Barriers, and Treatment Breakthroughs
This podcast reviews accurate diagnosis of ATTR and development of effective treatment plans. Experts also discuss early detection strategies, including genetic testing to identify U.S.-relevant variants linked to hereditary ATTR.
Diagnostic Imaging Strategies for Cardiac Amyloidosis
This podcast will focus on multimodality cardiac imaging approaches and the application of diagnostic findings which contribute to an accurate diagnosis of ATTR-CM, specifically in differentiating ATTR-CA from AL-CA, and how to determine treatment options.
Pathophysiology and Clinical Features of ATTR Cardiac Amyloidosis
No Longer a “Rare” Disease and Still Underdiagnosed
HCPs play a key role in matching ATTR-CM patients to newly available treatments. This podcast reviews guideline-based, multimodal imaging and clinical diagnostics, along with the latest terminology, treatments, and recommendations for this increasingly recognized disease.
Pharmacotherapy for Cardiac Amyloidosis
In this podcast, experts will discuss the latest pharmacologic recommendations and their evolution in the treatment of cardiac amyloidosis. They will delineate the different potential therapeutic targets for the pharmacotherapy of cardiac amyloidosis including TTR silencing, stabilization, and disruption.
Resources for Clinicians
This activity is supported by an independent educational grant from Pfizer.